We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Exhaled Breath Test Diagnosis of Cancer Assessed

By LabMedica International staff writers
Posted on 29 May 2018
Print article
Image: The GastroCHECK Gastrolyzer breath test monitor (Photo courtesy of coVita).
Image: The GastroCHECK Gastrolyzer breath test monitor (Photo courtesy of coVita).
In the United Kingdom, upper gastrointestinal symptoms account for at least 3% of consultations in primary care and many patients present with advanced-stage disease and only 38% of cases can be treated with a curative intent.

Early esophagogastric cancer (OGC) stage presents with nonspecific symptoms. Volatile organic compounds (VOCs) emitted from the human body have been of interest to scientists for several decades, with associations previously suggested between specific VOCs and breath and lung, bladder, and breast cancers.

In a multicenter diagnostic study, led by those at Imperial College London (UK), scientists recruited 335 patients, including 172 patients with esophagogastric cancer; a breath test demonstrated good diagnostic accuracy. Patients 18 years or older with upper gastrointestinal symptoms attending for endoscopy or surgery were eligible. In the cancer cohort only patients with histologically confirmed nonmetastatic esophagogastric adenocarcinoma (stage I-III) were included. All patients in the cancer cohort were sampled when they were neoadjuvant naive.

Patients were asked to perform a single deep nasal inhalation followed by complete exhalation via their mouth into secure 500-mL steel breath bag (GastroCHECK, coVita, Santa Barbara, CA, USA) via a 1-mL Luer-lok syringe. Patients in the cancer and control groups were recruited consecutively. Breath samples were returned to a central laboratory for selected ion flow tube mass spectrometry (SIFT-MS) analysis. Histopathology examination of tissues obtained via endoscopy or from surgically resected specimens was carried out. The reference test was considered positive on OGC histopathology diagnosis.

The scientific team reported that patients in the OGC group were older (median [IQR] age 68 [60-75] versus 55 [41-69] years) and had a greater proportion of men (134 [82.2%]) versus women (81 [47.4%]) compared with the control group. Of the 163 patients with OGC, 123 (69%) had tumor stage T3/4, and 106 (65%) had nodal metastasis on clinical staging. The predictive probabilities generated by this 5-VOCs diagnostic model were used to generate a receiver operator characteristic curve, with good diagnostic accuracy, area under the curve of 0.85. This translated to a sensitivity of 80% and specificity of 81% for the diagnosis of OGC.

The authors concluded that their study shows the potential of breath analysis in noninvasive diagnosis of OGC in the clinical setting as the validation study showed a sensitivity of 80% and a specificity of 81% for the breath test to diagnose esophagogastric cancer. The study was published May 17, 2018, in the journal JAMA Oncology.

Related Links:
Imperial College London
coVita

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Autoimmune Vasculitis Test
AESKULISA MPO
New
Uric Acid and Blood Glucose Meter
URIT-10

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.